The Irkutsk plant of the Pharmasyntez Group of Companies is going to produce about 600,000 packages of the drug in 2021. The in-house pharmaceutical substance Favipiravir synthesized by BratskChemSyntez, one of the plants of the Pharmasyntez Group of Companies in the city of Bratsk, is going to be used for the production.

Marketing Authorization for the drug product Favibirin (INN Favipiravir) was received on December 3.

“The production capability of Pharmasyntez is represented by five plants in Russia. This allows us to produce and ship the demanded drugs in sufficient quantity promptly enough, primarily according to the needs of the domestic market. A number of other countries where Favibirin has not been registered yet also display a strong interest in this drug,” Vikram Punia, President of the Pharmasyntez Group of Companies, said.

Favipiravir is an antiviral drug that is particularly used for the treatment of a new coronavirus infection. It has passed clinical trials in China and Japan. 330 COVID-19 patients took part in clinical trials of Favipiravir in Russia. The Ministry of Healthcare of the Russian Federation has included Favipiravir in the list of recommendations for prevention, diagnosis and treatment of different forms of COVID-19 (mild, moderate and severe). It can be used both in outpatient and inpatient treatment.